News Archive

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

We’re honoring World Cancer Day with a new series called “Let’s Talk About the C Word: From Cancer to Cures” to address challenging conversations on cancer.

Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.

Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.